Navigation
banner

Biomarker Summit

2017-11-182017-12-272017-11-27
EARLY BIRD DISCOUNT! Register by Nov 27, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


PLENARY KEYNOTE SPEAKERS
Bruce W.M. Jordan

Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
 
About Speaker:

Dr. Bruce W.M. Jordan, Ph.D, FIBMS
VP, International Business Leader – Personalised Healthcare Solutions

Bruce joined the Roche Pharmaceuticals Herceptin team in Basel in 2005, leading the global HER2 Testing/Companion Diagnostics (CDx) activities. Since January 2013 he is VP - International Business Leader – Personalised Healthcare Solutions at Roche Diagnostics – Centralised and Pont of Care Solutions at their HQ in Rotkreuz, Switzerland.

He has worked on CDx development & commercialization out of both the Pharmaceuticals and Diagnostics Divisions over the past 11 years at Roche, across therapeutic areas such as Neurology, Immunology, Fertility and Oncology.

Bruce trained in Laboratory Medicine, graduating from the University of Portsmouth U.K. in 1994 with a BSc. (Hons.) Biomedical Sciences, subsequently gaining State Registration in Haematology and Transfusion Medicine at Southampton General Hospital. He has also worked at the Royal Marsden Hospital, London, and has a Ph.D. in cancer research from the University of Würzburg in Germany.

Bruce has also represented the diagnostics industry as a Corporate Representative at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and is a Fellow of the Institute of Biomedical Sciences (FIBMS) in the U.K., and a member of the European Society of Pharmacogenomics and Personalised Therapy (ESPT)

Nathan Price

Nathan Price
ISB Associate Director and Professor
Institute for Systems Biology
Nathan Price
ISB Associate Director and Professor
Institute for Systems Biology
 
About Speaker:
PLENARY SPEAKERS
Frédéric Baribaud

Frédéric Baribaud
Scientific Director
Janssen
Frédéric Baribaud
Scientific Director
Janssen
 
About Speaker:

Fred is an Associate Director in the Systems Pharmacology & Biomarkers department at Janssen R&D which he joined in 2006. He has been working in various inflammatory diseases working on patient stratification to enable individualized therapeutic treatments.
Fred holds a BS and a MS in Biochemistry from the University of Geneva, Geneva, Switzerland and a PhD in Biology from the University of Lausanne, Lausanne, Switzerland. Fred is a former UPENN postdoctoral fellow where he worked on HIV entry and a former employee of Incyte Inc, were he worked on target validation and was a discovery compound team co-lead for SMI development.

Gary Gustavsen

Gary Gustavsen
Vice President
Health Advances
Gary Gustavsen
Vice President
Health Advances
 
About Speaker:

Gary Gustavsen joined Health Advances in 2005 and leads its Personalized Medicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his Bachelors degree in Biomedical Engineering from Duke University and his Masters degree in Biomedical Engineering from Stony Brook University.

 

 

John Schilling

John Schilling
Director & Advisor of Diagnostics
Eli Lilly
John Schilling
Director & Advisor of Diagnostics
Eli Lilly
 
About Speaker:
Cristina Stefan

Cristina Stefan
Global Clinical Leader, Oncology Diagnostics
Roche
Cristina Stefan
Global Clinical Leader, Oncology Diagnostics
Roche
 
About Speaker:
Lorenzo Trippa

Lorenzo Trippa
Associate Professor, Biostatistics
Dana-Farber Cancer Institute, Harvard Medical School
Lorenzo Trippa
Associate Professor, Biostatistics
Dana-Farber Cancer Institute, Harvard Medical School
 
About Speaker:
Cardiovascular Biomarkers
DISTINGUISHED SPEAKERS
J. Brent Muhlestein

J. Brent Muhlestein
Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine, University of Utah
University of Utah
J. Brent Muhlestein
Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine, University of Utah
University of Utah
 
About Speaker:
Pei Pei Ping

Pei Pei Ping
Director, NIH BD2K Center of Excellence at UCLA; Professor, Medicine/Cardiology, and Bioinformatics
UCLA
Pei Pei Ping
Director, NIH BD2K Center of Excellence at UCLA; Professor, Medicine/Cardiology, and Bioinformatics
UCLA
 
About Speaker:
Szilard Voros

Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
 
About Speaker:

Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3’s platform is based on the largest-ever program using DNA and RNA sequencing, proteomics, metabolomics, lipidomics and other platforms. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute. He has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.

Inflammatory & Immunological Biomarkers
DISTINGUISHED SPEAKERS
Andrew Holman

Andrew Holman
Chief Executive Officer & Co-founder
Inmedix
Andrew Holman
Chief Executive Officer & Co-founder
Inmedix
 
About Speaker:
Toshiaki Kawakami

Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
 
About Speaker:

1978 MD, 1983 PhD from The University of Tokyo
1984-88 Postdoc at the NCI/NIH
1990 Assistant Professor, La Jolla Institute for Allergy and Immunology (LJI)
2000 Professor, LJI

Pierluigi Mauri

Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
 
About Speaker:

Pierluigi Mauri is chief of Proteomics and Metabolomics Labat ITB-CNR. He has a notable experience in the development and application of several technologies (HPLC, capillary electrophoresis, mass spectrometry) for the identification and quantification of several biomolecules in complex matrices. He has been involved in the study of the bioavailabily of several drugs in humans and animals.
He has set-up a proteomics laboratory based on the MudPIT (Multidimensional Protein Identification Technology), a gel-free approch (using two dimensional chromatography coupled to tandem mass spectrometry, 2DC-MS/MS) and a parallel computing system for proteomics. This instrumentation allows for the proteomic profiling of biological samples, without limitations, according to to protein molecular weight, pI or hydrophobicity and guarantees high productivity. Using this methodology, secreted proteins from tumor (FASEB 2005) and immune system cells (JEM, 2011, Immunity, 2016) have been characterized.
Furthermore, direct analysis of biological samples (JMS 2007), enzymatic complexes (Biochimie 2006), development of novel methodological approaches for studying switchredox proteins (JBC 2005 and 2006, JMB 2006), degenerative diseases (Blood, 2012) and structural and functional characterization of proteins (Biol. Chem. 2004, FEBS 2006) have been performed. His main investigations concern molecular profiles obtained by MS-based methodologies and focused on clinical applications (J Proteome Research,
2014; JACC 2013; Nature Commun, 2014; Cardiovasc Res. 2011; Biol Reprod. 2013), including computational methods (J Clin Bioinforma. 2013; Methods Enzymology, 2008) He is co-author of more than 150 scientific publications, he has participated in numerous international congresses and has taught in several metabolomics and proteomics courses.

Calixte Monast

Calixte Monast
Senior Scientist
Janssen R&D
Calixte Monast
Senior Scientist
Janssen R&D
 
About Speaker:
Neurological Biomarkers
DISTINGUISHED SPEAKERS
Richard Batrla-Utermann

Richard Batrla-Utermann
Medical Director
Roche
Richard Batrla-Utermann
Medical Director
Roche
 
About Speaker:
Andreas Jeromin

Andreas Jeromin
Chief Medical Officer
Quanterix
Andreas Jeromin
Chief Medical Officer
Quanterix
 
About Speaker:

Andreas Jeromin, PhD, has more than 25 years of experience in CNS clinical diagnostics and companion diagnostics and co-authors more than 150 publications. He is the founder of Atlantic Biomarkers, Inc., and currently the consulting Chief Medical Officer to Quanterix Corp.

Stephen J. Kolb

Stephen J. Kolb
Associate Professor, Department of Neurology and Biological Chemistry & Pharmacology; Director, Ohio State ALS/MND Multidisciplinary Clinic and Research Program
The Ohio State University Wexner Medical Center
Stephen J. Kolb
Associate Professor, Department of Neurology and Biological Chemistry & Pharmacology; Director, Ohio State ALS/MND Multidisciplinary Clinic and Research Program
The Ohio State University Wexner Medical Center
 
About Speaker:
Oncology Biomarkers
DISTINGUISHED SPEAKERS
Michael Heller

Michael Heller
Professor
University of California, San Diego
Michael Heller
Professor
University of California, San Diego
 
About Speaker:

Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. Dr. Heller was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) from 1976 to 1984. During that time, he carried out very early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production. He also development the first fluorescent resonant energy transfer (FRET) and chemiluminescent DNA oligonucleotide probes. Additionally, he oversaw the company sponsored research work at Cetus Corporation on their related recombinant DNA efforts for energy and chemical production, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987.  He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989.  He was a co-found of Nanotronics and Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for molecular diagnostic genotyping applications. Dr. Heller is now a Professor in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He has also recently co-founded a new company called Biological Dynamics which will be developing new sample to answer cancer diagnostic technology, which is based on novel dielectrophoretic (DEP) microarray technology developed in his lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology; with particular expertise in the areas of DNA probe diagnostics, DC electrophoretic and AC dielectrophoretic devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanocomponents. Dr. Heller has a respectable publication record, and has been an invited speaker to many scientific conferences and meetings related clinical/molecular diagnostics, DNA microarrays, biosensors, lab-on-a-chip devices, bio-MEMS and nanotechnology. He has over 50 issued US patents related to microelectronic chips, microarrays and integrated devices for DNA hybridization, miniaturized sample to answer diagnostic devices, biosensors, genomics, proteomics, nanotechnology and nanofabrication, nano-based DNA optical storage and for fluorescent energy transfer in DNA nanostructures. Dr. Heller has been a panel member for the White House (OSTP) National Nanotechnology Initiative 1999/2000; the NAS (NAE) Review of National Nanotechnology Initiative 2001-2002; the NAS(NAE) – Engineer for the 2020 - 2001/2002; and has also been involved in a number of NSF Nanotechnology Workshops.

Tony Pircher

Tony Pircher
Director of Immunochemistry
Biocept
Tony Pircher
Director of Immunochemistry
Biocept
 
About Speaker: